Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Innate and myeloid checkpoint antibodies act on macrophages, natural killer (NK) cells and other innate immune cells. Magrolimab blocks CD47, which binds signal-regulatory protein alpha (SIRPĪ±) on macrophages and suppresses phagocytosis of target cells. Monalizumab targets the inhibitory NK cell receptor NKG2A, which recognizes HLA-E on tumor cells. Axatilimab and cabiralizumab bind colony-stimulating factor 1 receptor (CSF1R) and are used to study tumor-associated macrophages in vitro and in vivo. Further antibodies target sialic acid-binding Ig-like lectins (Siglecs), TREM receptors and the activating receptor NKG2D.
Lifonebart is a humanized monoclonal antibody that specifically inhibits TREM2 (triggering receptor expressed on myeloid cells 2). This antibody isotype is human IgG1Īŗ and is suitable for research applications investigating the immune response and neuroinflammation. Lifonebart serves as a crucial tool for studying the role of TREM2 in various pathological conditions, including neurodegenerative diseases.
Out of stock
All 3 sizes